Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.64 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | MC3R | P41968 | 1/20 | 0.63 |
| ▸ | JAK3 | P52333 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15105075 | 0.93 | EGFR (0.85) | EGFRERBB2ERBB4 | |
| SCHEMBL18633090 | 0.93 | EGFR (0.85) | EGFRERBB2ERBB4 | |
| SCHEMBL15090806 | 0.93 | EGFR (0.85) | EGFRERBB2ERBB4 | |
| SCHEMBL10029549 | 0.93 | EGFR (0.85) | EGFRERBB2ERBB4 | |
| SCHEMBL15112797 | 0.93 | EGFR (0.80) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL15104577 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL15090473 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL15104579 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL18595919 | 0.91 | EGFR (0.77) | EGFRERBB2ERBB4GAKRIPK2 | |
| SCHEMBL18595812 | 0.91 | EGFR (0.79) | EGFRERBB2ERBB4GAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | XUANZHU PHARMA CO, LTD. (CN) | 2019-12-17 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO, LTD. (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | XUANZHU PHARMA CO LTD (CN) | 2017-10-26 | — | — | US | disclosed |
| US-9730934-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-08-15 | — | — | US | disclosed |
| US-9730934-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-08-15 | — | — | US | disclosed |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2013-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304305-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB2 1417/4885ERBB4 1431/4885 |
| US-20170333433-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB2 1417/4885ERBB4 1431/4885 |
| US-10507209-B2 | Quinazoline derivatives substituted by aniline, preparation method and use thereof | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB2 1417/4885ERBB4 1431/4885 |
| US-20130184297-A1 | QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF | NQO2, CHRM1, CHRM2 | EGFR 983/4885ERBB2 1417/4885ERBB4 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.